Therapeutic Area

Current drive is to find more targeted therapeutics rather than global immunosuppressants. Key assays are designed to test both small molecules and biologics such as cytokine neutralising antibodies, against the major drivers of autoimmunity including CD4 T cells, B cells and antigen presenting cells.

• Can you model specific autoimmune diseases in your assays? 

Yes, we have in vitro immune cell assays that model autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis and multiple sclerosis. Using these autoimmune disease models we can test novel therapeutics that target autoreactive immune responses. 

• Do you use diseased immune cells from autoimmune patients in your assays? 

Yes, we use immune cells from healthy donors and autoimmune patients to evaluate therapeutic mechanism of action (MOA) and translation into the disease setting. 

• Do you provide assays to evaluate B cell function in autoimmunity? 

Yes, we provide B cell function assays for autoimmunity using our tonsil organoid model or peripheral blood. The assays evaluate T cell: B cell cross talk, antigen-specific B cell proliferation, activation, antibody production (total IgG and isotype switching) and memory B cell responses. We also assess therapeutic effects on key B cell subsets such as naive, pre-GC, GC, memory, plasmablast/cytes. 

Our tailored approach to assay design and execution provides precise solutions for novel therapeutics, ensuring the success of your drug development programme. Visit our testimonial page to read how our immunology CRO services and collaborative efforts have helped our partners achieve quality outcomes to their immunology-focused enquiries.